StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) company profile

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.97−0.03 (-3.47%)

Close on Nov 18, 2026Market cap $134.14MP/E –Yield –

About ALX Oncology

Pharmaceutical Preparations, SIC 2834

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on advancing novel cancer therapies to prolong patient survival. Its clinical pipeline centers on two investigational candidates: evorpacept and ALX2004. Evorpacept is an engineered CD47-blocking fusion protein that pairs an affinity-enhanced extracellular domain of SIRPα with an inactivated Fc domain, designed to prevent hematologic toxicities while enabling the immune system to engulf cancer cells in combination with other anti-cancer treatments. The company evaluates evorpacept in clinical studies alongside targeted anti-cancer antibodies, small molecules, and checkpoint inhibitors, notably in combination with trastuzumab and chemotherapy for patients with metastatic HER2-positive breast cancer. ALX2004 is an antibody-drug conjugate targeting epidermal growth factor receptor (EGFR).

The company maintains its principal executive offices in South San Francisco, California. Its clinical research activities involve evaluating investigational therapies across patient populations, with evorpacept having been administered to approximately 800 subjects in clinical trials.

Summary of the business section of ALX Oncology's latest annual report, written by StockData.

Company profile

Company

Legal name
ALX Oncology Holdings Inc
Headquarters
South San Francisco, CA
Address
323 Allerton Avenue 94080
Phone
(650) 466-7125
Employees
43, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Francisco, California

Stock & identifiers

Ticker
ALXO
Exchange
Nasdaq
IPO date
Jul 17, 2020
Shares outstanding
138M, Jul 30, 2026
Public float
$18.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1810182
CUSIP
00166B105
ISIN
US00166B1052
FIGI
BBG00VR8SDG8
Share class FIGI
BBG00VR8SF73
EIN
85-0642577

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jason LettmannCHIEF EXECUTIVE OFFICER, Director2,393,474
Shelly WongSVP, FINANCE AND CAO87,828
Barbara KlenckeChief Medical Officer120,000
Jeff E. KnightChief Dev & Operating Officer–
Harish ShantharamChief Financial Officer75,000
Jaume PonsPRESIDENT & CSO579,388
Corey S. GoodmanDirector8,453,038
Rekha HemrajaniDirector33,000
J. Scott GarlandDirector–
Alan B. SandlerDirector–
Daniel J. CurranDirector–
Chris H. TakimotoDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Jason Lettmann
$2.47M$1.32M$1.20M$10–
FY2025
Jaume Pons
$0$0$1.20M$10–
FY2024
Jason Lettmann
$6.64M-$11.21M$2.69M$15–
FY2024
Jaume Pons
$0$0$2.69M$15–
FY2023
Jason Lettmann
$4.86M$15.23M$1.34M$132–
FY2023
Jaume Pons
$2.75M$5.62M$1.34M$132–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Jason Lettmann
Chief Executive Officer
$724.50K$1.45M$298.86K–$2.47M-63%
Harish Shantharam
Chief Financial Officer
$464.48K$1.08M$151.91K–$1.70M–
Shelly Wong
Senior Vice President, Finance and Chief Accounting Officer
$435.59K$361.94K$142.87K–$940.41K-38%
Jaume Pons, Ph.D.
Former President and Chief Scientific Officer
$259.20K$64.53K–$650.00K$973.73K-68%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 17, 2020
Offer price
$19.00
Securities offered
8,500,000
Gross proceeds
$161.50M
Exchange
Nasdaq
First trading day
Jul 17, 2020
First-day close
$30.00+57.9%
Lock-up ends (est.)
Jan 13, 2021

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 43 employees, 11 of whom hold Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?